1801.HK+7.77%14.3%
2565.HK-46.54%14.3%
3933.HK-35.44%14.3%
AMGN+21.06%14.3%
LLY+53.92%14.3%
NVO-31.16%14.3%
ROG.SW+19.13%14.3%
As of Jul 10, 2026, 7:14 AM ET
GLP-1 Long '24: GLP1 Drug Producer Constituents
| Company | Wgt | Premarket % | 1D % | 10D % | MTD % | YTD % | IranWar % | LibDay % | 1Yr % | Mkt Cap |
|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and CompanyLLY | 14.3% | 0.44% | 0.09% | -1.06% | 2.12% | 13.24% | 15.68% | 48.73% | 53.92% | $1.15T |
Roche Holding AGROG.SW | 14.3% | 0.00% | 0.15% | 0.08% | 0.32% | -5.05% | -17.66% | 20.82% | 19.13% | $312.89B |
Novo Nordisk A/SNVO | 14.3% | 0.93% | -0.02% | 1.12% | 0.23% | -3.93% | 30.52% | -28.37% | -31.16% | $217.21B |
Amgen Inc.AMGN | 14.3% | 0.24% | -1.19% | 0.85% | 0.63% | 11.09% | -6.32% | 18.95% | 21.06% | $196.25B |
Innovent Biologics, Inc.1801.HK | 14.3% | 3.88% | 0.17% | 7.95% | 8.56% | 12.45% | 1.31% | 72.01% | 7.77% | $19.11B |
The United Laboratories International Holdings Limited3933.HK | 14.3% | 1.33% | -2.70% | 5.46% | 6.96% | -22.60% | -30.80% | -35.21% | -35.44% | $2.27B |
PegBio Co., Ltd.2565.HK | 14.3% | 28.75% | 0.18% | -4.25% | 3.83% | -92.04% | -91.45% | -52.50% | -46.54% | $200.6M |
| Theme return | — | 5.08% | -0.47% | 1.45% | 8.57% | -22.15% | -24.65% | 16.11% | 7.78% | — |
| Average | 14.3% | 5.08% | -0.47% | 1.45% | 3.24% | -12.41% | -14.10% | 6.35% | -1.61% | $270.57B |
| Median | 14.3% | 0.93% | 0.09% | 0.85% | 2.12% | -3.93% | -6.32% | 18.95% | 7.77% | $196.25B |
| Std Dev | 0.0% | 9.74% | 1.02% | 3.77% | 3.12% | 34.64% | 36.74% | 42.88% | 34.13% | $375.11B |
| Min | 14.3% | 0.00% | -2.70% | -4.25% | 0.23% | -92.04% | -91.45% | -52.50% | -46.54% | $200.6M |
| Max | 14.3% | 28.75% | 0.18% | 7.95% | 8.56% | 13.24% | 30.52% | 72.01% | 53.92% | $1.15T |
| % Positive Tickers | 85.71% | 57.14% | 71.43% | 100.00% | 42.86% | 42.86% | 57.14% | 57.14% |
About this theme
GLP-1 Long '24: GLP1 Drug Producer tracks 7 publicly listed stocks in this theme: 1801.HK, 2565.HK, 3933.HK, AMGN, LLY, NVO, ROG.SW. See the constituent table for details.